Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features

January 4, 2005BMC PsychiatryOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to compare the efficacy of duloxetine in patients with major depressive disorder exhibiting melancholic features versus those without.
Pooled data from 8 double-blind, placebo-controlled clinical trials
Patients received duloxetine (40-120 mg/d) or placebo for up to 9 weeks
Efficacy was measured using the Hamilton Rating Scale for Depression and other scales.
Duloxetine showed significant improvement over placebo in both groups (p < .001 for HAMD17 total score)
Probabilities of response were 74.7% for duloxetine versus 42.2% for placebo in melancholic patients (p < .001)
Remission rates were higher in duloxetine-treated melancholic patients (44.4% vs. 24.7%, p = .002).

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Randomized trial compares duloxetine's efficacy in melancholic versus non-melancholic patients, indicating similar outcomes.

No takes yet. Share an insight, caveat, or question.

Mallinckrodt et al. (2005) studied this question.

View Full Paper

Ask AI

Bookmark

Share